Zomedica Corp. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Therapeutics at $7.2 million, 72% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
39
|
10
|
10
|
9
|
10
|
8
|
7
|
6
|
8
|
| Therapeutics |
27
+4.7%
share 70.2%
|
7
+7.5%
share 72.4%
|
7
+9.2%
share 71.0%
|
6
-2.0%
share 66.2%
|
7
+3.8%
share 70.7%
|
7
share 82.4%
|
6
share 88.8%
|
6
share 91.4%
|
7
share 90.3%
|
| Diagnostics |
5
+63.2%
share 12.1%
|
2
+113.3%
share 16.4%
|
1
+77.3%
share 14.6%
|
1
+72.8%
share 11.0%
|
1
-8.4%
share 6.7%
|
1
share 9.4%
|
1
share 11.2%
|
1
share 8.6%
|
1
share 9.7%
|
| Development Services |
7
share 17.7%
|
1
+66.9%
share 11.2%
|
1
share 14.4%
|
2
share 22.9%
|
2
share 22.6%
|
1
share 8.2%
|
—
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZOMDF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- Alberta, Canada
- Headquarters
- Ann Arbor, MI
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1684144
- Former names
- Zomedica Pharmaceuticals Corp. (until Sep 28, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.